The study, published Feb. 4 in Vaccines, looked at data from 296 UConn Health workers, including 46 who already had COVID-19. Participants were vaccinated with either the Pfizer or the Moderna mRNA vaccine. Researchers studied their blood for neutralizing antibodies at two months, five months and nine months post-vaccination.
Participants who had symptoms following the vaccination such as fever, aches or a sore arm had a stronger and longer lasting neutralizing antibody response. The response outperformed both those who had COVID-19 before the vaccine and those who had not, according to the study.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.